Navigation Links
Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement
Date:5/23/2011

contraindicated in the following clinical situations where bleeding could lead to significant morbidity or death:

  • Active internal bleeding
  • Recent (within 3 months) hemorrhagic stroke
  • Recent (within 2 months) intracranial or intraspinal surgery, or severe head trauma
  • Trauma with an increased risk of life-threatening bleeding
  • Presence of an epidural catheter
  • Intracranial neoplasm or mass lesion or evidence of cerebral herniation

WARNINGS and PRECAUTIONS

Bleeding is the most common serious adverse effect associated with Xigris therapy. Each patient being considered for therapy with Xigris should be carefully evaluated and anticipated benefits weighed against potential risks associated with therapy.

Certain conditions, many of which led to exclusion from the Phase 3 clinical trial (PROWESS), are likely to increase the risk of bleeding with Xigris therapy. Therefore, for patients with severe sepsis who have one or more of the following conditions, the increased risk of bleeding should be carefully considered when deciding whether to use Xigris therapy:

  • Concurrent therapeutic dosing of heparin to treat an active thrombotic or embolic event
  • Platelet count <30,000 x 10,000,000/L, even if the platelet count is increased after transfusions
  • Prothrombin time-INR >3.0
  • Recent (within 6 weeks) gastrointestinal bleeding
  • Recent administration (within 3 days) of thrombolytic therapy
  • Recent administration (within 7 days) of oral anticoagulants or glycoprotein IIb/IIIa inhibitors
  • Recent administration (within 7 days) of aspirin >650 mg per day or other platelet inhibitors
  • Recent (within 3 months) ischemic stroke
  • Intracranial arteriovenous malformation or aneurysm
  • Known bleeding diathesis
  • Chronic severe hepatic disease '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
2. David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly
3. Lilly Provides Its Perspective in Response to Amylin Lawsuit
4. Lilly Provides Statement in Response to Amylin Lawsuit
5. Lilly USA, LLC Launches TruAssist for Patients
6. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
7. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
8. Amylin Pharmaceuticals Files Suit Against Eli Lilly
9. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
10. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
11. Lilly and Medtronic Announce Drug-Device Collaboration for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... S.C., Oct. 21, 2011 Federal, state and local ... growing biomedical research effort with the dedication of a ... for major diseases. The complex, housing 78 ... traditional research approach by combining scientists from different fields ...
... division of Sanofi (EURONEXT: SAN and NYSE: ... study evaluating the immunogenicity and safety of an investigational ... of age and older. Currently licensed influenza vaccines target ... a given year. The data were presented at the ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... Arizona State University is seeking aspiring ... their ideas into solutions, products and services in ... is recruiting participants for AREA48 (Applied Regional Economic ... early-stage entrepreneurs with opportunities to access human and ... ASU is particularly seeking participation from retirees, veterans ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
(Date:5/21/2013)... Phoseon Technology will present their advanced ... Annual IMI European Ink Jet Conference (June 5-6, ... continues to invest in product development to enable breakthrough ... LED curing in printing applications. Phoseon currently has ... offering both air cooled and water cooled solutions to ...
(Date:5/21/2013)... 21, 2013 Global Proving Ground (GPG), ... the largest online retailer of health and fitness supplements, ... sports show, Warrior Island. “We cast the show ... & Twitter, with our unique social networking platform,” states ... elite fighters on an island in the Pacific Ocean, ...
Breaking Medicine News(10 mins):Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... Center have identified and announced the most common causes ... with red, sore itchy rashes was caused by exposing ... fragnance, cosmetics, metals, creams, etc. ,The July ... 10 causes of contact dermatitis that were recently identified ...
... tests conducted by the Analytical Services Tasmania King Island's water ... conducted tests which showed high content of lead in the ... testing done by the council which found no problem with ... metals and the results were announced with days of testing. ...
... report of the Washington Post, the department of health of Washington, ... every district resident, between 14years and 84years, to ... , The launching of the campaign, to be named ... the 12th annual National HIV Testing Day. ,Gregg Pane, ...
... (AIIMS) dean is considering quitting the institution //, as ... colleagues and misguided students. ,The dean R.C.Deka, ... expert in cochlear implant surgery is now contemplating leaving ... by his colleagues and students. He explained that he ...
... in their new studies that the analysis of the placenta ... ,Scientists from the University of Yale stated that they believe ... birth by analysing and seeking out certain biological abnormalities present ... developmental disorder that affects a child's social learning and communication ...
... Varca in Goa it is found that Indians eating ... //The two day conference mainly analyzed the Indian population ... This would further worsen the situation by increasing the ... diabetes and other fatal diseases. Experts and medical practitioners ...
Cached Medicine News:Health News:Another Senior Doctor From AIIMS Contemplates Leaving Due to Infighting 2Health News:Another Senior Doctor From AIIMS Contemplates Leaving Due to Infighting 3Health News:Analysis of Placenta Helps In Diagnosis of Autism At Birth 2
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: